Multi-asset returns over the month. Commodities strong again, bond markets materially negative, on the back of the most aggressive tightening cycle seen since 1994.

In the US tech stocks rebounded meaningfully from their sell-off.

Asia and Asia tech had a rebound over the last week, and an almighty sell-off over the month as a function of a) regulatory intervention against state/tech champions (the “social dividend” or “common prosperity” frame) and b) fears of US regulatory push back over the audit access of dual listed companies. For c) you could also include the impact of higher real rates. Australia, with the heavy commodity and banking exposure performed very well on higher prices and higher rates beta.

US homebuilders continue to sell-off, as higher mortgage rates imperil the hither-to-fore very strong US housing market.

Australian homebuilders (especially those with US exposure) sold off as well, with JHX, REH, RWC, and even ABC declining. Otherwise FPH (high multiple) downgrading as Omicron requires less respiratory intervention for afflicted patients, and a generally diverse basket of monthly underperformers.

The outperformers remains largely commodity and banking stocks.

Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Please note that past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.

Receive our investment insights

Something went wrong. Please check your entries and try again.